Please ensure Javascript is enabled for purposes of website accessibility

Why Progyny Stock Popped 27%

By Rich Smith - May 13, 2020 at 12:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Q1 earnings beat, and Progyny is lining up to do it again in Q2.

What happened

Shares of employer-sponsored fertility benefits manager Progyny (PGNY 1.31%) are up a bouncing baby 26.8% (as of 12:10 p.m. EDT) after the company reported a quadrupling in quarterly profit in its Q1 2020 earnings report last night.  

Wall Street analysts had forecast that the fertility specialist would earn just $0.02 per share (still twice last year's haul) on sales of $71.8 million. In fact, Progyny earned twice what the analysts had expected -- $0.04 per diluted share -- and eclipsed sales estimates, too -- $81 million booked.  

Mother lying down and holding a happy baby

Image source: Getty Images.

So what

Progyny's business was not unaffected by the COVID-19 crisis that struck in Q1. To the contrary, "Our members' access to care was meaningfully disrupted during the first quarter," said CEO David Schlanger. Despite the pandemic, however, Progyny managed to grow its sales 72% year over year -- and quadruple its profit.

Importantly, the implication here seems to be that Progyny would have done even better had the coronavirus not happened, and investors like the sound of that -- a lot.

Now what

More good news: The company says it is "well-positioned to successfully manage COVID-related impacts" going forward, and clinics in its network "have implemented, or are currently implementing, safety protocols and other necessary measures in order to be up and running for their full range of treatments over the course of the next several weeks."

Already Progyny is seeing "week-to-week acceleration in both the volume of patient appointments as well as the dispensing of fertility medications." In the coming quarters, says company president Pete Anevski, Progyny is "looking forward to our clinics building back up to their pre-COVID patient volumes," and keeping this growth story going.

Granted, Q2 results are forecast to be only about $45 million in revenues, with a net loss on the bottom line. Seeing as Wall Street was predicting sales of only $15 million and change, however, investors are taking even this "bad" news as pretty darn good.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Progyny, Inc. Stock Quote
Progyny, Inc.
$29.43 (1.31%) $0.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.